公司資料
Scholar Rock 股價、新聞與催化劑
- 股票代碼:
- SRRK
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
52.05 USD (-0.89%)
收盤價
最後更新: 2026年8月17日
5.35B USD
市值
股價為何變動
The latest company update was “Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. SRRK changed 0.89% and closed at $52.05 on Aug 17, 2026, indicating a relatively limited closing-price reaction to this company update.
公司概覽
Myostatin Biology
Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways.
Apitegromab
Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy. It is designed as an add-on to therapies that address the underlying genetic cause.
Additional Pipeline
Scholar Rock is applying its platform to additional neuromuscular and metabolic indications where modulation of muscle biology may provide clinical benefit.
未來催化劑
- FDA action on the apitegromab BLA by September 30, 2026.
- Potential U.S. launch of apitegromab immediately following approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。